Expert Directory
Censorship, First Amendment, Freedom of Speech and Press, Journalism, Media Ethics, Media Literacy, Popular Music History
Ken Paulson is director of the Free Speech Center, former dean of the College of Media and Entertainment at Middle Tennessee State University (MTSU) and former editor-in-chief of USA Today, where he remains a columnist writing about First Amendment and media issues. He is the host of “The Songwriters,” a television show on PBS, featuring interviews with Nashville Songwriters Hall of Fame inductees. Paulson is a board member of the Hall of Fame. Paulson’s areas of expertise include: The First Amendment Paulson founded the Free Speech Center at MTSU in 2019. He was executive director of the First Amendment Center at Vanderbilt University and served as the center’s president and CEO before that. Paulson speaks widely on First Amendment issues and has been quoted extensively in media outlets including the New York Times, Wall Street Journal, USA TODAY, ESPN, CBS Evening News and Newsweek. Paulson has testified before Congress as a First Amendment expert. He has a juris doctorate and is a member of both the Illinois and Florida bars. Paulson was the host of the Emmy-honored television PBS program "Speaking Freely.," As the author of "Freedom Sings," he created a multimedia show celebrating the First Amendment that has toured campuses for the past 20 years. His “The Bill of Rights: The Remix” has been in residency at the Country Music Hall of Fame since 2017. Paulson teaches Mass Media Law and Free Expression, the Media and the American People at MTSU. Journalism Throughout his career, Paulson has drawn on his background as a journalist and lawyer, serving as editor or managing editor of newspapers in five states. He was on the team of journalists who founded USA Today before moving on to manage newsrooms in N.Y., Wis., N.J., Fla., and finally USA TODAY. He and his colleague John Seigenthaler spoke to more than 5,000 journalists and media professionals about the importance of a free press. Popular Music Paulson has written professionally about music over four decades, beginning at the Chicago-based Environs Magazine. He currently hosts the NPT show “The Songwriters” as well as the “Americana One” radio show and podcast. He created “Music Matters,” a radio feature that celebrates songs with impact. Paulson is a member of MTSU’s Recording Industry faculty and teaches History of the Recording Industry. Paulson is a member of the Tennessee Entertainment Commission and a former member of The Mayor’s Music Council in Nashville. Honors He was named fellow of the Society of Professional Journalists, "the highest honor SPJ bestows upon a journalist for extraordinary contributions to the profession." He has received the Robert S. Abbott Memorial Award for Meritorious Service in Mass Communications from the Southern Regional Press Institute. He was elected to the University of Illinois’ Illini Publishing Hall of Fame. Paulson was honored with the American Press Institute Lifetime Service Award. He has received the Missouri Honor Medal for Distinguished Service in Journalism. He is a graduate of the University of Illinois College of Law and the University of Missouri School of Journalism.
Prescription Drug Cost, video game industry, Banking, behavior analysis, peer-to-peer, Lending, Economics, Marketing, Management Science, Nursing Home, Econometrics
Andrew Ching is a professor in the Carey Business School at the Johns Hopkins University, where he is jointly appointed to the Department of Economics and the Bloomberg School of Public Health. He is currently serving as an Associate Editor for Management Science, and a member of editorial boards for Marketing Science and Journal of Marketing Research. His research focuses on developing new empirical structural models and estimation methods to understand the forward-looking, strategic, learning and bounded rational behavior of consumers and firms. He has applied these methods to several industries including prescription drugs, nursing homes, payment methods, retail banking, peer-to-peer lending, and video games. He has published in Econometrica, Mangement Science, Marketing Science, Journal of Banking and Finance, Journal of Applied Econometrics, and others. He has received Young Economist Award from the European Economic Association, Honorable Mention of Dick Wittink Prize Award, and several major research grants from Social Sciences and Humanities Research Council in Canada.
David Maloney, MD, PhD
Medical Director, Cellular Immunotherapy Integrated Research Center at Fred Hutch
Fred Hutchinson Cancer CenterCAR T-cell therapy, Immunotherapy, Chimeric antigen receptor T-cell, Lymphoma, Leukemia, Myeloma, cancer immunotherapies, Blood Cancers, ofatumumab, Arzerra, Hematopoietic
Physician-scientist Dr. David Maloney is at the forefront of clinical trials to develop cell therapies for blood and other cancers, including understanding side effects of CAR T’s and how to deliver them in outpatient settings. A renowned researcher and clinician focusing on cancer immunotherapies and CAR T-cell therapies, he recently presented findings from the TRANSCEND trial for CD19 CAR T. This study showed that patients had improved quality-of-life (reduced fatigue and pain symptoms) starting six months after receiving CAR T-cell therapy. Dr. Maloney focuses on using genetically engineered T cells (such as CAR-T) to treat patients with leukemia, lymphoma, myeloma and selected other cancers without causing graft vs. host disease that has been associated with transplantation. He was instrumental in developing and testing rituximab, the first antibody-based cancer drug on the market – one that has transformed the treatment of certain leukemias and lymphomas. He is also an expert on blood-forming (hematopoietic) stem cell transplantation (HCT) in using a matched donor’s (allogeneic) or a patient’s own (autologous) stem cells in treatments for patients with hematologic malignancies. Recognizing that standard pre-transplant regimens are too toxic for many patients, Dr. Maloney and Fred Hutch colleagues are evaluating approaches that use antibodies to deliver radioactivity or cancer-killing drugs directly to tumors. They have also developed a less toxic, “reduced intensity” (nonmyeloablative) regimen that can more safely provide long-term remissions for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin Lymphoma (NHL) and myeloma after allogeneic HCT. Autologous HCT followed by reduced intensity allogenic HCT (tandem HCT) has proven effective for refractory NHL and myeloma patients. Dr. Maloney and colleagues have learned that nearly all of the anti-tumor activity of allogeneic HCT comes from the specific graft-vs-tumor activities of donor immune T cells, showing that antitumor immunity can be curative. Unfortunately, these T cells can also cause dangerous “graft-vs-host” effects on normal tissues. Dr. Maloney continues exploring the use of antibodies as anti-cancer therapies, including newer anti-CD20 antibodies (e.g. ofatumumab, Arzerra®) for NHL patients, as well as radiolabeled antibodies, drug-carrying antibodies and unlabeled antibodies as targeted pre-transplant “conditioning” or as “maintenance” to extend remissions after allogeneic transplantation. As medical director of the Cellular Immunotherapy Integrated Research Center at Fred Hutch, Dr. Maloney cares for patients at the Bezos Family Immunotherapy Clinic at Seattle Cancer Care Alliance, the Hutch’s clinical-care partner. He is also professor of medicine in the Division of Oncology at the University of Washington.
Gary Lyman, MD, MPH
Senior lead for health care quality and policy, HICOR
Fred Hutchinson Cancer CenterHealthcare economics, cost of cancer care, cancer costs, value-based cancer care, Financial toxicity, Drug Costs, cost-effective cancer care, HICOR, disparities in cancer care, biosimilars, cancer outcomes, Hutchinson Institute for Cancer Outcomes Research
While many researchers worldwide are trying to find cures for cancer, Dr. Gary Lyman has an equally daunting task: finding a cure for cancer’s skyrocketing costs and the financial toll it can take on patients and their families. Dr. Lyman is an internationally recognized thought leader in cancer care delivery, supportive care and health care policy. His research compares the effectiveness of novel diagnostic and therapeutic strategies; examines clinical decision-making; explores risk modeling and precision medicine; assesses health technology research and synthesis; and delves into the factors that drive disparities in cancer care. In 2018, he co-co-authored a New England Journal of Medicine paper on biosimilars and what their imminent debut might mean for cancer patients, the health care industry and society. He also led an American Society of Clinical Oncology (ASCO) panel that published a position statement on biosimilars in the Journal of Clinical Oncology. A medical oncologist, hematologist and public health researcher who focuses on comparative effectiveness, health technology assessment, and health services and outcomes research, he also is interested in cancer prevention, pharmaco-economics, and cancer treatment and supportive care for the elderly. Dr Lyman is among the top 1% of investigators by citations in Web of Science. In addition to his work at the Hutch, Dr. Lyman holds leadership positions within the American Society of Clinical Oncology as well as the SWOG Cancer Research Network, for which he serves as executive officer for Cancer Care Delivery, Symptom Control and Quality of Life Research. Dr. Lyman serves as a senior lead for health care quality and policy within the Hutchinson Institute for Cancer Outcomes Research, or HICOR.
Kathleen Sutcliffe, PhD
Bloomberg Distinguished Professor
Johns Hopkins University Carey Business SchoolOrganizational Change, Resilience, Risk Management, Medical Mistakes, Uncertainty, Organization, Johns Hopkins, Johns Hopkins Carey Business School
Kathleen M. Sutcliffe, PhD, is the Bloomberg Distinguished Professor of Business and Medicine at Johns Hopkins University. Her research explores how organizations and their members cope with uncertainty and unexpected surprises, and how organizations can be designed to be more reliable and resilient. She is currently investigating these issues in healthcare as well as in wild-land firefighting, oil and gas exploration, and other dynamic high-risk industries. Her 2019 book, Still Not Safe: Patient Safety and the Middle-Managing of American Medicine, looks at how the health care industry has responded to medical errors over the last 20 years.
Health Care, Health Care Policy, health care economics, Public Health, Johns Hopkins Bloomberg School Of Public Health, Johns Hopkins Carey Business School
Dan Polsky is a Bloomberg Distinguished Professor of Health Policy and Economics at Johns Hopkins University. Prior to joining Hopkins served as Executive Director of the Leonard Davis Institute of Health Economics from 2012 - 2019 and was a professor at the University of Pennsylvania in the Perelman School of Medicine and the Wharton School of Business. His research seeks an advanced understanding of the cost and quality tradeoff of health care intervention that addresses care, access, coverage, and payment.
causal inference, Economics, Behavioral Economics, Behavioral Science, Environmental Policy, Johns Hopkins, Johns Hopkins Carey Business School
Paul J. Ferraro, PhD, is the Bloomberg Distinguished Professor of Business and Engineering at Johns Hopkins University. Dr. Ferraro has a joint faculty appointment in the Whiting School of Engineering and the Carey Business School. His research focuses on behavioral economics and the design and evaluation of environmental programs in the private and public sectors. Because these research areas are multi-disciplinary and applied, he collaborates with scientists and engineers from a variety of social, natural and physical science disciplines, as well as practitioners in the field.
Phillip Phan, PhD
Alonzo and Virginia Decker Professor of Strategy and Entrepreneurship
Johns Hopkins University Carey Business SchoolTechnology Transfer and Commercialization, Entreprenership, Medicine, strategic management , Technology, Johns Hopkins, Johns Hopkins Carey Business School
Phillip Phan, PhD, is the Alonzo and Virginia Decker Professor of Strategy and Entrepreneurship and joined the Johns Hopkins Carey Business School in 2008. He is a professor in the research track with expertise in the areas of technology entrepreneurship and strategic management.
Marketing, Consumer decision-making, Decision Making, Inequality, Inefficiency, marketing cues, comparison shopping, consumer judgment, Preferences, Johns Hopkins Carey Business School
Meng Zhu is a professor at the Johns Hopkins Carey Business School and specializing in marketing and consumer decision-making. She joined the Carey Business School after receiving her PhD from Carnegie Mellon University. Her research interests include consumer judgment and decision-making, contextual influences on preference construction, the causes of and solutions to inefficiency and inequality, and the impact of marketing cues and comparison standards.
prosocial behavior, Intrinsic Reward, Extrinsic Values, Moral Behavior, moral decisions, Global Health, Experimental Economics, development economics, Labor, Human Resources, Johns Hopkins Carey Business School, Johns Hopkins Medicine
Mario Macis, PhD (Economics, University of Chicago) is an associate professor in the research track with expertise in the areas of prosocial behavior, morally controversial transactions, global health, experimental economics, development economics, and labor economics. He is also Affiliate Faculty at the JHU Berman Institute of Bioethics, Associate Faculty at the Armstrong Institute for Patient Safety and Quality at JHU Medicine, Faculty Research Fellow in the National Bureau of Economic Research (NBER), and Research Fellow at the Institute for the Study of Labor (IZA). Dr. Macis has been a consultant for the World Bank, the International Labor Organization, the National Marrow Donor Program, and the United Nations Development Programme.
Health Economics, Children's Health, development economics, Health Policy, Johns Hopkins Carey Business School, congestion pricing
Emilia Simeonova, PhD (Economics from Columbia University in 2008) joined Johns Hopkins Carey Business School in 2013 from Tufts University. Between 2011-2012 she was a research fellow at the Center for Health and Wellbeing at Princeton University. Emilia’s research interests in the economics of health care delivery, patient adherence to therapy and the interaction between physicians and patients, racial disparities in health outcomes, the long-term effects of shocks to children's health and intergenerational transmission of health. Her research has been funded by the National Institutes of Health, the National Science Foundation, the Swedish Research Council and the Danish Academy of Sciences.
Chemistry, Nanoscience, Biophysical Chemistry, materials science
In the quest for molecular-level information, molecular-scale tools are a powerful and desirable scientific goal. Our research program is centered on development of a new class of nanofabricated devices based on nanopores. In its simplest form, a nanopore is nothing more than a molecular-sized hole in an insulating membrane. Yet even in this configuration, it is cable of being used to detect and manipulate single molecules. With careful device engineering, it is possible to create powerful sensors for the detection of disease biomarkers at low levels early in the onset of disease or of trace amounts of toxins -- to name two targets. Configured differently, nanopore-based devices can be used to probe intermolecular interactions that underpin biological function -- ranging from testing new pharmaceutical drug candidates to exploring the fundamental biophysics governing processes such as antibody-antigen recognition. Our research is focused on conceiving, fabricating and optimizing the nanopore devices that will make possible these challenging goals. Research Interests include: How do molecules work, and how can we better put them to work for us? Bioanalytical, biophysical, & materials chemistry and nanoscience.
Oncology, Breast Cancer, Hematologic Cancers
Dr. Priyanka Sharma is an oncologist in Fairway, Kansas and is affiliated with University of Kansas Hospital. She received her medical degree from Baroda Medical College and has been in practice between 11-20 years. Her specialties are: oncologists diagnose and treat cancers of all types. They use diagnostic tools like biopsies, endoscopies, X-ray and other imaging, nuclear medicine, and blood tests. Cancer surgeons, or surgical oncologists, remove tumors, while medical oncologists treat cancers with chemotherapy. Radiation oncologists use multiple forms of radiation in an effort to eliminate tumors.
Roy A. Jensen, MD
Director at The University of Kansas Cancer Center and Director at Kansas Masonic Research Institute (KMCRI)
University of Kansas Cancer CenterPathology, Laboratory Medicine, Anatomy, Cell Biology
Roy A. Jensen, M.D. earned his bachelor’s degree in Biology and Chemistry from Pittsburg State University in 1980. He graduated from Vanderbilt University School of Medicine in 1984, and remained there to complete a residency in Anatomic Pathology and a Surgical Pathology fellowship under the direction of Dr. David L. Page. Following his clinical training he accepted a biotechnology training fellowship at the National Cancer Institute in the laboratory of Dr. Stuart Aaronson. He returned to Vanderbilt in 1991 and was appointed an assistant professor in the Departments of Pathology and Cell Biology. In 1993 Dr. Jensen was appointed as an investigator in the Vanderbilt-Ingram Cancer Center and assumed the management of the Human Tissue Acquisition and Pathology Shared Resource. Dr. Jensen was promoted to associate professor of Pathology and Cell Biology in 1996, and was appointed as an associate professor of Cancer Biology in 2001. In 2004, Dr. Jensen returned home to Kansas and was appointed the William R. Jewell, M.D. Distinguished Kansas Masonic Professor, the director of The University of Kansas Cancer Center, the director of the Kansas Masonic Cancer Research Institute, professor of Pathology and Laboratory Medicine, and professor of Anatomy and Cell Biology at the University of Kansas Medical Center. He also holds appointments as a professor in the Department of Molecular Biosciences at the University of Kansas-Lawrence and as professor in Cancer Biology at The University of Kansas Medical Center. Dr. Jensen is currently serving as president of the Association of American Cancer Institutes (AACI) and is a member of several scientific and professional societies including the American Association for Cancer Research, the American Association for the Advancement of Science, the American Society for Cell Biology, the American Society for Investigative Pathology, and the United States and Canadian Academy of Pathology. He currently has over 150 scientific publications and has lectured widely on the clinical and molecular aspects of breast cancer pathology. Dr. Jensen's research interests are focused on understanding the function of BRCA1 and BRCA2 and their role in breast and ovarian neoplasia; and in the characterization of premalignant breast disease both at the morphologic and molecular levels. His laboratory was instrumental in demonstrating the role of BRCA1 in the growth control of normal and malignant cells and in how loss of functional BRCA1 contributes to the development of breast cancer. Since becoming director of The University of Kansas Cancer Center in 2004, he has recruited a world-class leadership team and successfully led that team in achieving designation for The University of Kansas Cancer Center as a National Cancer Institute designated cancer center.
Gastrointestinal Cancer, Pancreatic Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer
Weijing Sun, MD, FACP, is a Director of Division of Medical Oncology in University of Kansas School of Medicine, and an Associate Director of University of Kansas Cancer Center. He specializes in the treatment of colorectal cancer. Dr. Sun is board-certified in internal medicine and medical oncology. He received his medical degree from Shanghai Medical College, Fudan University, in Shanghai. He completed his residency in internal medicine at Loyola University Medical Center in Maywood, Ill., and his hematology-oncology fellowship at the University of Pennsylvania in Philadelphia. Dr. Sun is a member of the American Medical Association, the American Society of Clinical Oncology, the American Association of Cancer Research, the Eastern Cooperative Group of Oncology Gastrointestinal Cancer Core Committee, the American College of Physicians – Internal Medicine, the NCI Gastrointestinal Cancer Steering Committee Hepatobiliary Task Force, and serves on the American Society of Clinical Oncology Scientific Program and Membership Committee. In addition, Dr. Sun has been recognized on U.S. News & World Report’s American Top Doctors list.
Raphael Gottardo, PhD
Scientific Director, Translational Data Science Integrated Research Center
Fred Hutchinson Cancer Centerdata-driven immunotherapy, technology convergence, Data science research, translational data, Computational Biology, Computational Science, Bioinformatics, Biostatistics, Stochastic, Flow Cytometry, data-driven research, high-speed genome sequencing
Dr. Raphael Gottardo is a computational biologist who specializes in applying rapidly evolving ideas in data science to solving problems in cancer and related diseases. As scientific director of the Translational Data Science Integrated Research Center, he is at the center of the busy intersection of biology, data science and technology at Fred Hutchinson Cancer Research Center. His goal is to expand data-driven innovations for patients by cultivating a cross-disciplinary environment in which doctors and laboratory scientists work seamlessly with their colleagues in biostatistics and computational sciences to take advantage of the flood of information made possible by advanced technologies. The aim is to bring scientific discoveries from research labs to the bedside sooner using data-driven approaches. To do so, bench scientists and clinical researchers from many corners of the Hutch work collaboratively with experts in data science. Much of his work is focused on profiling the cellular components of the human immune system – using data science to understand how to make immunotherapies work better for patients. “It’s when you get into the details that it really becomes interesting,” he said. “The immune system is very complex, and it turns out we don’t know a whole lot about it yet. Looking at these single-cell technologies generating massive amounts of data has brought me to really cool statistical and computational challenges.” Dr. Gottardo’s own research involves the development of computational tools for vaccine and immunology studies, including high-throughput experiments that may use flow cytometry or high-speed genome sequencing. His current studies include: • Statistical and computational analysis of flow cytometry data • Development of statistical and computational methods for single-cell genomics • Immune responses to malaria and HIV infection and immunization within the Human Immunology Project Consortium (HIPC) • Development of the HIPC database and research portal (www.immunespace.org) • Contribution to the Bioconductor project, an open computing resource for genomics • Leadership for the Vaccine and Immunology Statistical Center of the Collaboration for AIDS Vaccine Discovery of the Bill and Melinda Gates Foundation • Leadership for the Vaccine Statistical Support (VSS) Global Health Vaccine Accelerating Platform (GH-VAP) of the Bill and Melinda Gates Foundation Dr. Gottardo is the J. Orin Edson Foundation Endowed Chair at Fred Hutch and a member of the Vaccine and Infectious Disease and Public Health Sciences Divisions. He, along with other Fred Hutch researchers, is co-leading a collaboration with the Allen Institute for Immunology to chart the human immune system by harnessing big data and emerging technologies. An affiliate professor of statistics at the University of Washington, he teaches courses in stochastic modeling, bioinformatics and statistical computing and supervises biostatistics and statistics doctoral students on statistical-methods research for high-dimensional omics data analysis
---
Dr. David Baskin is board certified by the American Board of Neurological Surgery. He completed his medical training at Mount Sinai School of Medicine of the CUNY, and a residency at the University of California. He completed a fellowship in neural protection at the University of Capetown Medical School. He also completed a fellowship in brain endorphins at the University of California. Baskin is the primary investigator for a number of clinical trials looking at different novel diagnostics and treatments for primary brain tumors and autistic spectrum disorder. His clinical focus is on the treatment of brain and spinal tumors.
---
Dr. Aldona Spiegel certified in plastic surgery by the American Board of Plastic Surgery. She completed her medical training at the University of Ottawa Faculty of Medicine. Spiegel completed a residency in general surgery and plastic surgery at John Hopkins Hospital. She also completed a residency in plastic surgery and a fellowship in microsurgery at Baylor College of Medicine. Spiegel's clinical focus is microsurgery, breast reconstruction, breast sensation and specialized perforator flaps (DIEP, SIEA, SGAP flaps). Her clinical expertise allows her to focus on research in innovative surgical techniques, such as muscle-preserving flaps.
---
Dr. Kevin Varner is board certified by the American Board of Orthopedic Surgery. He completed medical training, an orthopedic surgery residency and a general surgery internship at Baylor College of Medicine. He also completed a clinical fellowship in foot and ankle surgery at John Hopkins University. Varner's clinical areas of interest are tibia fractures and sports-related injuries of the foot and ankle. Varner serves as a consulting physician for the Houston Astros, a head team physician for the Houston Ballet and a team orthopedist for the Houston Texans.
---
Dr. Josh Harris is board certified by the American Board of Orthopedic Surgery in orthopedic sports medicine. He completed his medical training and a residency in orthopedic surgery at Ohio State University College of Medicine. He also completed a fellowship in Orthopedic Surgery Sports Medicine at Rush University Medical Center. His main clinical focus is on sports injury and arthroscopic surgery for the treatment of various sports-related injuries. Harris conducts research in orthopedic sports medicine and hip preservation. Harris serves as the team physician of the Houston Ballet, and the consulting physician of Rice University Athletics.
Please enter your username and
password to login
close
-
News keyboard_arrow_right
Latest News Coronavirus News Currently Embargoed News Research News Releases Google Fact Check Research Alert Preprints Marketplace News with Video/Audio Multimedia
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right